TY - JOUR
T1 - Cancer-associated venous thromboembolic disease, version 2.2021
AU - Streiff, Michael B.
AU - Holmstrom, Bjorn
AU - Angelini, Dana
AU - Ashrani, Aneel
AU - Elshoury, Amro
AU - Fanikos, John
AU - Fertrin, Kleber Yotsumoto
AU - Fogerty, Annemarie E.
AU - Gao, Shuwei
AU - Goldhaber, Samuel Z.
AU - Gundabolu, Krishna
AU - Ibrahim, Ibrahim
AU - Kraut, Eric
AU - Leavitt, Andrew D.
AU - Lee, Alfred
AU - Lee, Jason T.
AU - Lim, Ming
AU - Mann, Janelle
AU - Martin, Karlyn
AU - McMahon, Brandon
AU - Moriarty, John
AU - Morton, Colleen
AU - Ortel, Thomas L.
AU - Paschal, Rita
AU - Schaefer, Jordan
AU - Shattil, Sanford
AU - Siddiqi, Tanya
AU - Sudheendra, Deepak
AU - Williams, Eliot
AU - Hollinger, Liz
AU - Nguyen, Mai Q.
N1 - Publisher Copyright:
© JNCCN
PY - 2021/10
Y1 - 2021/10
N2 - NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Cancer-Associated Venous Thromboembolic Disease focus on the prevention, diagnosis, and treatment of patients with cancer who have developed or who are at risk for developing venous thromboembolism (VTE). VTE is a significant concern among cancer patients, who are at heightened risks for developing as well as dying from the disease. The management of patients with cancer with VTE often requires multidisciplinary efforts at treating institutions. The NCCN panel comprises specialists from various fields: cardiology, hematology/hematologic oncology, internal medicine, interventional radiology, medical oncology, pharmacology/pharmacy, and surgery/surgical oncology. This article focuses on VTE prophylaxis for medical and surgical oncology inpatients and outpatients, and discusses risk factors for VTE development, risk assessment tools, as well as management methods, including pharmacological and mechanical prophylactics. Contraindications to therapeutic interventions and special dosing, when required, are also discussed.
AB - NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Cancer-Associated Venous Thromboembolic Disease focus on the prevention, diagnosis, and treatment of patients with cancer who have developed or who are at risk for developing venous thromboembolism (VTE). VTE is a significant concern among cancer patients, who are at heightened risks for developing as well as dying from the disease. The management of patients with cancer with VTE often requires multidisciplinary efforts at treating institutions. The NCCN panel comprises specialists from various fields: cardiology, hematology/hematologic oncology, internal medicine, interventional radiology, medical oncology, pharmacology/pharmacy, and surgery/surgical oncology. This article focuses on VTE prophylaxis for medical and surgical oncology inpatients and outpatients, and discusses risk factors for VTE development, risk assessment tools, as well as management methods, including pharmacological and mechanical prophylactics. Contraindications to therapeutic interventions and special dosing, when required, are also discussed.
UR - http://www.scopus.com/inward/record.url?scp=85118264157&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85118264157&partnerID=8YFLogxK
U2 - 10.6004/jnccn.2021.0047
DO - 10.6004/jnccn.2021.0047
M3 - Review article
C2 - 34666313
AN - SCOPUS:85118264157
SN - 1540-1405
VL - 19
SP - 1181
EP - 1201
JO - JNCCN Journal of the National Comprehensive Cancer Network
JF - JNCCN Journal of the National Comprehensive Cancer Network
IS - 10
ER -